THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS

THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS

Aim: To evaluate retrospectively the efficacy and safety of entecavir in treatment-naïve patients with hepatitis B viral infection.Materials and methods: Based on patient medical documentation, we analyzed the results of clinical, virologic and instrumental assessment of 36 patients with chronic hep...

Full description

Bibliographic Details
Main Authors:	L. I. Mel'nikova, L. Yu. Il'chenko
Format:	Article
Language:	Russian
Published:	MONIKI 2016-02-01
Series:	Alʹmanah Kliničeskoj Mediciny
Subjects:	acute hepatitis b chronic hepatitis b treatment entecavir
Online Access:	https://www.almclinmed.ru/jour/article/view/109

Similar Items

Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection
by: Kai-Chi Chang, et al.
Published: (2016-10-01)

Severe Acute Hepatitis B Treated with Entecavir
by: Andrea Tosti, et al.
Published: (2011-01-01)

Long-term entecavir efficacy retention in the treatment of chronic hepatitis B with an outcome to hepatic cirrhosis caused by its resistant virus strain
by: O O Znoĭko, et al.
Published: (2012-11-01)

Evaluation of the Efficacy of Entecavir and Tenofovir in the Treatment of Chronic Hepatitis B: A Retrospective Study
by: Arzu ŞENOL, et al.
Published: (2019-12-01)

Comparison of entecavir and adefovir for the treatment of chronic hepatitis B
by: Si-Hai Zhao, et al.

Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
by: Rosanna Villani, et al.
Published: (2015-06-01)

Entecavir in the treatment of chronic hepatitis B: multicenter randomized trials and real clinical practice
by: D T Abdurakhmanov, et al.
Published: (2014-11-01)

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
by: Dae Won Jun, et al.
Published: (2013-06-01)

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
by: Joon Yeul Nam, et al.
Published: (2017-12-01)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
by: Nobuharu Tamaki, et al.
Published: (2020-06-01)

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
by: Han Na Choi, et al.
Published: (2015-03-01)

A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient
by: Ji Hyun Song, et al.
Published: (2016-04-01)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
by: Joo An Hwang, et al.
Published: (2015-06-01)

Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy
by: Xia-Xia Zhang, et al.
Published: (2016-01-01)

Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01)

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis
by: Cesar Henriquez-Camacho, et al.
Published: (2023-11-01)

Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B
by: Po-Ke Hsu, et al.
Published: (2022-05-01)

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
by: Hsin-Wei Fang, et al.
Published: (2024-04-01)

Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients
by: Hyung Min Yu, et al.
Published: (2015-01-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
by: Jin Shang, et al.
Published: (2021-09-01)

Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients
by: Yuan-wang Qiu, et al.
Published: (2016-02-01)

Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
by: Xingmei Liao, et al.
Published: (2023-11-01)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015-04-01)

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
by: Byoung Kuk Jang
Published: (2020-07-01)

A comparison between entecavir and tenofovir in chronic hepatitis B in the clinical practice: a single-center experience
by: Salvatore Sollima, et al.
Published: (2015-06-01)

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis
by: Zeynal Dogan, et al.
Published: (2015-01-01)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
by: EunYoung Ze, et al.
Published: (2014-09-01)

Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial
by: Cho EJ, et al.
Published: (2018-11-01)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
by: Jung Gil Park, et al.
Published: (2015-09-01)

Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study
by: Ming-Lun Yeh, et al.
Published: (2016-11-01)

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients
by: Chia-Chi Wang, et al.
Published: (2014-11-01)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
by: Yi He, et al.
Published: (2022-07-01)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
by: Minghui Li, et al.
Published: (2022-09-01)

Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants
by: Ping Li, et al.
Published: (2017-04-01)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
by: Yang YM, et al.
Published: (2017-09-01)

Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?
by: Giorgio Maria Saracco, et al.
Published: (2022-02-01)

Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice
by: Ezequiel Ridruejo, et al.
Published: (2014-05-01)

Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir
by: Diana Horta, et al.

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
by: Ze-Hong Huang, et al.
Published: (2022-03-01)